Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: Inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa

Biochemical Pharmacology

Volumn 80, Issue 12, 2010, Pages 1887-1894

  Gambari Roberto, R ^a   Borgatti, Monica ^a   Bezzerri, Valentino ^b   Nicolis, Elena ^b   Lampronti, Ilaria ^a   Dechecchi, Maria Cristina ^b   Mancini, Irene ^a   Tamanini, Anna ^b   Cabrini, Giulio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Inflammation; NF kappaB; Peptide nucleic acids; PNA DNA chimeras; Transcription factor decoy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE NUCLEIC ACID;

CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LUNG CYSTIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW;

ANIMALS; CELL LINE; CYSTIC FIBROSIS; CYTOKINES; DNA; HUMANS; INFLAMMATION; INTERLEUKIN-8; MOLECULAR TARGETED THERAPY; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS; PSEUDOMONAS AERUGINOSA;

EID: 78049424081     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.047     Document Type: Review

References (87)

1. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23:146-158.
2. Verkman A.S., Song Y., Thiagarajah J.R. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003, 284:C2-15.
3. Machen T.E. Innate immune response in CF airway epithelia: hyperinflammatory?. Am J Physiol Cell Physiol 2006, 291:C218-C230.
4. Puchelle E., De Bentzmann S., Hubeau C., Jacquot J., Gaillard D. Mechanisms involved in cystic fibrosis airway inflammation. Pediatr Pulmonol 2001, 23(Suppl. 200):143-145.
5. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Hilliard J.B., Ghnaim H., et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995, 152:2111-2118.
6. Jones A.M., Martin L., Bright-Thomas R.J., Dodd M.E., McDowell A., Moffitt K.L., et al. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 2003, 22:503-506.
7. Becker M.N., Sauer M.S., Muhlebach M.S., Hirsh A.J., Wu Q., Verghese M.W., et al. Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med 2004, 169:645-653.
8. Koehler D.R., Downey G.P., Sweezey N.B., Tanswell A.K., Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004, 31:377-381.
9. Zabner J., Karp P., Seiler M., Phillips S.L., Mitchell C.J., Saavedra M., et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 2003, 284:L844-L854.
10. Finkbeiner W.E., Carrier S.D., Teresi C.E. Reverse transcription-polymerase chain reaction (RT-PCR) phenotypic analysis of cell cultures of human tracheal epithelium, tracheobronchial glands, and lung carcinomas. Am J Respir Cell Mol Biol 1993, 9:547-556.
11. DiMango E., Ratner A.J., Bryan R., Tabibi S., Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998, 101:2598-2605.
12. Dechecchi M.C., Nicolis E., Bezzerri V., Vella A., Colombatti M., Assael B.M., et al. MPB-07 reduces the inflammatory response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells. Am J Respir Cell Mol Biol 2007, 36:615-624.
13. Borgatti M., Bezzerri V., Mancini I., Nicolis E., Dechecchi M.C., Lampronti I., et al. Induction of IL-6 gene expression in a CF bronchial epithelial cell line by Pseudomonas aeruginosa is dependent on transcription factors belonging to the Sp1 superfamily. Biochem Biophys Res Commun 2007, 357:977-983.
14. Bezzerri V., Borgatti M., Nicolis E., Lampronti I., Dechecchi M.C., Mancini I., et al. Transcription factor oligodeoxynucleotides to NF-{kappa}B inhibit transcription of IL-8 in bronchial cells. Am J Respir Cell Mol Biol. 2008, 39:86-96.
15. Nichols D., Chmiel J., Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008, 34:146-162.
16. Bodas M., Vij N. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 2010, 9:346-356.
17. Kieninger E., Regamey N. Targeting inflammation in cystic fibrosis. Respiration 2010, 79:189-190.
18. Rottner M., Kunzelmann C., Mergey M., Freyssinet J.M., Martínez M.C. Exaggerated apoptosis and NF-kappaB activation in pancreatic and tracheal cystic fibrosis cells. FASEB J 2007, 21:2939-2948.
19. Muselet-Charlier C., Roque T., Boncoeur E., Chadelat K., Clement A., Jacquot J., et al. Enhanced IL-1beta-induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF-kappaB signaling. Biochem Biophys Res Commun 2007, 357:402-407.
20. Ferreiro D.U., Komives E.A. Molecular mechanisms of system control of NF-kappaB signaling by IkappaBalpha. Biochemistry 2010, 49:1560-1567.
21. Wan F., Lenardo M.J. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res 2010, 20:24-33.
22. Solt L.A., May M.J. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 2008, 42:3-18.
23. Mingyan Y., Xinyong L., De Clercq E. NF-kappaB: the inducible factors of HIV-1 transcription and their inhibitors. Mini Rev Med Chem 2009, 9:60-69.
24. Stevens M., De Clercq E., Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev 2006, 26:595-625.
25. Tergaonkar V. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 2006, 38:1647-1653.
26. Shifera A.S. Protein-protein interactions involving IKKgamma (NEMO) that promote the activation of NF-kappaB. J Cell Physiol 2010, 223:558-561.
27. Courtois G., Gilmore T.D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006, 25:6831-6843.
28. Dzau V.J. Transcriptional factor decoy. Circ Res 2002, 90:1234-1236.
29. Piva R., Gambari R. Transcription factor decoy (TFD) in breast cancer research and treatment. Technol Cancer Res Treat 2002, 1:405-416.
30. Mann M.J., Dzau V.J. Therapeutic application of transcriptional factor decoy oligonucleotides. J Clin Invest 2000, 106:1071-1075.
31. Morishita R., Sugimoto T., Aoki M., Kida I., Tomita N., Moriguchi A., et al. In vivo transfection of cis element " decoy" against nuclear factor-kB binding site prevents myocardial infarction. Nat Med 1997, 3:894-899.
32. Tomita T., Takano H., Tomita N., Morishita R., Kaneko M., Shi K., et al. Transcription factor decoy for NF-kappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000, 39:749-757.
33. Penolazzi L., Lambertini E., Borgatti M., Piva R., Cozzani M., Giovannini I., et al. Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem Pharmacol 2003, 66:1189-1198.
34. Piva R., Penolazzi L., Lambertini E., Giordano S., Gambari R. Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. Apoptosis 2005, 66:1079-1094.
35. Piva R., Penolazzi L., Zennaro M., Bianchini E., Magri E., Borgatti M., et al. Induction of apoptosis of osteoclasts by targeting transcription factors with decoy molecules. Ann N Y Acad Sci 2006, 1091:509-516.
36. Penolazzi L., Borgatti M., Lambertini E., Mischiati C., Finotti A., Romanelli A., et al. Peptide nucleic acid-DNA decoy chimeras targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Int J Mol Med 2004, 14:145-152.
37. Lambertini E., Penolazzi L., Tavanti E., Pocaterra B., Schincaglia G.P., Torreggiani E., et al. Modulation of expression of specific transcription factors involved in the bone microenvironment. Minerva Biotecnol 2008, 20:69-78.
38. Borgatti M., Bezzerri V., Mancini I., Nicolis E., Dechecchi M.C., Rizzotti P., et al. Silencing of genes coding for transcription factors: biological effects of decoy oligonucleotides on cystic fibrosis bronchial epithelial cells. Minerva Biotecnol 2008, 20:79-84.
39. Cooper J.A., Parks J.M., Carcelen R., Kahlon S.S., Sheffield M., Culbreth R. Attenuation of interleukin-8 production by inhibiting nuclear factor-kappaB translocation using decoy oligonucleotides. Biochem Pharmacol 2000, 59:605-613.
40. Griesenbach U., Scheid P., Hillery E., de Martin R., Huang L., Geddes D.M., et al. Anti-inflammatory gene therapy directed at the airway epithelium. Gene Ther 2000, 7:306-313.
41. Griesenbach U., Cassady R.L., Cain R.J., MduBois R.M., Geddes D.M., Alton E.W. Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation. Gene Ther 2002, 9:1109-1115.
42. Morishita R., Tomita N., Kaneda Y., Ogihara T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 2004, 4:139-146.
43. De Stefano D., De Rosa G., Carnuccio R. NFkappaB decoy oligonucleotides. Curr Opin Mol Ther 2010, 12:203-213.
44. Piva R., Penolazzi L., Borgatti M., Lampronti I., Lambertini E., Torreggiani E., et al. Apoptosis of human primary osteoclasts treated with molecules targeting nuclear factor-kappaB. Ann N Y Acad Sci 2009, 1171:448-456.
45. Isomura I., Morita A. Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006, 50:559-563.
46. Park G.Y., Christman J.W. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr Drug Targets 2006, 7:661-668.
47. Roth M., Black J.L. Curr Drug Targets. Transcription factors in asthma: are transcription factors a new target for asthma therapy? 2006, 7:589-595.
48. Edwards M.R., Bartlett N.W., Clarke D., Birrell M., Belvisi M., Johnston S.L. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009, 121:1-13.
49. Yoshizumi T., Ikeda Y., Kaneda Y., Sueishi K. Ex vivo transfer of nuclear factor-kappaB decoy ameliorates hepatic cold ischemia/reperfusion injury. Transplant Proc 2009, 41:1504-1507.
50. Takahashi T., Togo S., Kumamoto T., Watanabe K., Kubota T., Ichikawa Y., et al. Transfection of NF-kappaB decoy oligodeoxynucleotides into macrophages reduces murine fatal liver failure after excessive hepatectomy. J Surg Res 2009, 154:179-186.
51. Suzuki M., Inoue G., Gemba T., Watanabe T., Ito T., Koshi T., et al. Nuclear factor-kappa B decoy suppresses nerve injury and improves mechanical allodynia and thermal hyperalgesia in a rat lumbar disc herniation model. Eur Spine J 2009, 18:1001-1007.
52. Shimizu H., Nakagami H., Morita S., Tsukamoto I., Osako M.K., Nakagami F., et al. New treatment of periodontal diseases by using NF-kappaB decoy oligodeoxynucleotides via prevention of bone resorption and promotion of wound healing. Antioxid Redox Signal 2009, 11:2065-2075.
53. Penolazzi L., Magri E., Lambertini E., Bianchini E., Piva R., Gambari R. In vivo local transfection of a cis element decoy mimicking an estrogen receptor alpha gene promoter region induces apoptosis of osteoclasts following application of orthodontic forces to rat teeth. Apoptosis 2006, 11:1653-1656.
54. Kim K.H., Lee E.S., Cha S.H., Park J.H., Park J.S., Chang Y.C., et al. Transcriptional regulation of NF-kappaB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy. Exp Mol Pathol 2009, 86:114-120.
55. Kimura S., Egashira K., Chen L., Nakano K., Iwata E., Miyagawa M., et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009, 53:877-883.
56. De Stefano D., De Rosa G., Maiuri M.C., Ungaro F., Quaglia F., Iuvone T., et al. Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 2009, 60:33-40.
57. Li Y.T., He B., Wang Y.Z., Wang J. Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice. Respir Res 2009, 10:79.
58. Nielsen P.E., Egholm M., Berg R.H., Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991, 254:1497-1500.
59. Demidov V.V., Frank-Kamenetskii M.D. Sequence-specific targeting of duplex DNA by peptide nucleic acids via triplex strand invasion. Methods 2001, 23:108-122.
60. Nielsen P.E. Antisense peptide nucleic acids. Curr Opin Mol Ther 2000, 2:282-287.
61. Nielsen P.E. Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem 2001, 8:545-550.
62. Püschl A., Tedeschi T., Nielsen P.E. Pyrrolidine PNA: a novel conformationally restricted PNA analogue. Org Lett 2000, 2:4161-4163.
63. Larsen H.J., Bentin T., Nielsen P.E. Antisense properties of peptide nucleic acid. Biochim Biophys Acta 1999, 1489:159-166.
64. Nielsen P.E. PNA Technology. Mol Biotechnol 2004, 26:233-248.
65. Gambari R. Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Des 2001, 7:1839-1862.
66. Rasmussen F.W., Bendifallah N., Zachar V., Shiraishi T., Fink T., Ebbesen P., et al. Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. Oligonucleotides 2006, 16:43-57.
67. Shi F., Gounko N.V., Wang X., Ronken E., Hoekstra D. In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel. Oligonucleotides 2007, 17:122-133.
68. Weyermann J., Lochmann D., Zimmer A. Comparison of antisense oligonucleotide drug delivery systems. J Control Release 2004, 100:411-423.
69. Shi F., Hoekstra D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J Control Release 2004, 97:189-209.
70. Nastruzzi C., Cortesi R., Esposito E., Gambari R., Borgatti M., Bianchi N., et al. Liposomes as carriers for DNA-PNA hybrids. J Control Release 2000, 68:237-249.
71. Cortesi R., Mischiati C., Borgatti M., Breda L., Romanelli A., Saviano M., et al. Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles. AAPS J 2004, 6:10-21.
72. Mischiati C., Borgatti M., Bianchi N., Rutigliano C., Tomassetti M., Feriotto G., et al. Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter. J Biol Chem 1999, 274:33114-33122.
73. Saviano M., Romanelli A., Bucci E., Pedone C., Mischiati C., Bianchi N., Borgatti M., et al. Computational procedures to explain the different biological activity of DNA/DNA DNA/PNA and PNA/PNA hybrid molecules mimicking NF-kappaB binding sites. J Biomol Struct Dyn 2000, 18:353-362.
74. Uhlmann E. Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function. Biol Chem 1998, 379:1045-1052.
75. Romanelli A., Pedone C., Saviano M., Bianchi N., Borgatti M., Mischiati C., et al. Molecular interactions with nuclear factor kappaB (NF-kappaB) transcription factors of a PNA-DNA chimera mimicking NF-kappaB binding sites. Eur J Biochem 2001, 268:6066-6075.
76. Borgatti M., Boyd D.D., Lampronti I., Bianchi N., Fabbri E., Saviano M., Pedone C., et al. Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter. Oncol Res 2005, 15:373-383.
77. Borgatti M., Lampronti I., Romanelli A., Pedone C., Saviano M., Bianchi N., et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003, 278:7500-7509.
78. Moggio L., Romanelli A., Gambari R., Bianchi N., Borgatti M., Fabbri E., et al. Alternate PNA-DNA chimeras (PNA-DNA)(n): synthesis, binding properties and biological activity. Biopolymers 2007, 88:815-822.
79. Gambari R. Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem 2004, 11:1253-1263.
80. Borgatti M., Romanelli A., Saviano M., Pedone C., Lampronti I., Breda L., et al. Resistance of decoy PNA-DNA chimeras to enzymatic degradation in cellular extracts and serum. Oncol Res 2003, 13:279-287.
81. Borgatti M., Breda L., Cortesi R., Nastruzzi C., Romanelli A., Saviano M., et al. Cationic liposomes as delivery systems for double-stranded PNA-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors. Biochem Pharmacol 2002, 64:609-616.
82. Borgatti M., Finotti A., Romanelli A., Saviano M., Bianchi N., Lampronti I., et al. Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression. Curr Drug Targets 2004, 5:735-744.
83. Mischiati C., Sereni A., Finotti A., Breda L., Cortesi R., Nastruzzi C., et al. Complexation to cationic microspheres of double-stranded peptide nucleic acid-DNA chimeras exhibiting decoy activity. J Biomed Sci 2004, 11:697-704.
84. Penolazzi L., Borgatti M., Lambertini E., Mischiati C., Finotti A., Romanelli A., et al. Peptide nucleic acid-DNA decoy chimeras targeting NF-kappaB transcription factors: Induction of apoptosis in human primary osteoclasts. Int J Mol Med 2004, 14:145-152.
85. Nelson D.E., Ihekwaba A.E., Elliott M., Johnson J.R., Gibney C.A., Foreman B.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004, 306:704-708.
86. Ashall L., Horton C.A., Nelson D.E., Paszek P., Harper C.V., Sillitoe K., et al. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science 2009, 324:242-246.
87. Xu X.S., Hong X., Wang G. Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol 2009, 2:15-22.